美国 · SEC FORM 4
Adverum Biotechnologies, Inc.
ADVM · — · CIK 0001501756 · Healthcare
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
0 同一窗口内观察到的 Form 4 交易行
0 sales · 0 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-12-08 · Fischer Laurent · $506.9K
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出无
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
当前 180 天窗口内没有 Form 4 交易事件。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-12-08 · Fischer Laurent.
近期 Form 4 活动
3买入
4卖出
26其他 Form 4 交易行
14SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他0 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景 capture is under review for ADVM. Last attempt: 2026-10-18T21:13:29.657793+00:00. —
空头余额
FINRA 报告中没有该股票代码的空头余额。
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-08 | Fischer Laurent | 买入 (P) | Common Stock | 117,614 | USD 4.31 | USD 506,916 | SEC 申报 ↗ |
| 2025-12-05 | Soparkar Peter | 买入 (P) | Common Stock | 50,000 | USD 4.22 | USD 211,000 | SEC 申报 ↗ |
| 2025-12-05 | Fischer Laurent | 买入 (P) | Common Stock | 11,085 | USD 4.24 | USD 47,000 | SEC 申报 ↗ |
| 2025-04-23 | Leonard Braden Michael | 买入 (P) | Common Stock | 50,000 | USD 2.98 | USD 149,000 | SEC 申报 ↗ |
| 2025-04-22 | Leonard Braden Michael | 买入 (P) | Common Stock | 300,000 | USD 3.00 | USD 900,000 | SEC 申报 ↗ |
| 2025-04-02 | Leonard Braden Michael | 买入 (P) | Common Stock | 15,209 | USD 4.04 | USD 61,444 | SEC 申报 ↗ |
| 2025-03-31 | Leonard Braden Michael | 买入 (P) | Common Stock | 19,566 | USD 4.38 | USD 85,699 | SEC 申报 ↗ |
| 2025-03-27 | Leonard Braden Michael | 买入 (P) | Common Stock | 16,593 | USD 5.19 | USD 86,118 | SEC 申报 ↗ |
| 2025-03-27 | Leonard Braden Michael | 买入 (P) | Common Stock | 16,593 | USD 5.19 | USD 86,118 | SEC 申报 ↗ |
| 2025-03-27 | Leonard Braden Michael | 买入 (P) | Common Stock | 16,593 | USD 5.19 | USD 86,118 | SEC 申报 ↗ |
| 2025-03-26 | Leonard Braden Michael | 买入 (P) | Common Stock | 20,407 | USD 5.04 | USD 102,851 | SEC 申报 ↗ |
| 2025-03-26 | Leonard Braden Michael | 买入 (P) | Common Stock | 20,407 | USD 5.04 | USD 102,851 | SEC 申报 ↗ |
| 2025-03-26 | Leonard Braden Michael | 买入 (P) | Common Stock | 20,407 | USD 5.04 | USD 102,851 | SEC 申报 ↗ |
| 2025-03-20 | Leonard Braden Michael | 买入 (P) | Common Stovk | 30,600 | USD 5.61 | USD 171,666 | SEC 申报 ↗ |
| 2025-03-19 | Leonard Braden Michael | 买入 (P) | Common Stock | 25,000 | USD 4.94 | USD 123,500 | SEC 申报 ↗ |
Form 4 申报证据
33 transaction lines in the latest 365-day window; 152 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-09 | Svoronos Dawn | U (U) | Common Stock | 5,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Soparkar Peter | U (U) | Common Stock - Restricted Stock Units | 13,125 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Soparkar Peter | U (U) | Common Stock - Performance Stock Units | 157,333 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-09 | Svoronos Dawn | U (U) | Common Stock | 5,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Soparkar Peter | U (U) | Common Stock - Restricted Stock Units | 13,125 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Soparkar Peter | U (U) | Common Stock - Performance Stock Units | 157,333 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Soparkar Peter | U (U) | Common Stock | 80,189 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Soparkar Peter | 奖励／授予 (A) | Common Stock - Performance Stock Units | 150,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | Seyedkazemi Setareh | U (U) | Common Stock - Restricted Stock Units | 8,125 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Seyedkazemi Setareh | U (U) | Common Stock - Performance Stock Units | 88,332 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Seyedkazemi Setareh | U (U) | Common Stock | 54,874 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Seyedkazemi Setareh | 奖励／授予 (A) | Common Stock - Performance Stock Units | 85,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | Scopa James Paul | U (U) | Common Stock | 10,333 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Rubinstein Linda M | U (U) | Common Stock - Restricted Stock Units | 8,125 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Rubinstein Linda M | U (U) | Common Stock - Performance Stock Units | 42,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Rubinstein Linda M | U (U) | Common Stock | 61,150 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Rubinstein Linda M | 期权行权／转换 (M) | Common Stock | 48,750 | USD 4.20 | USD 204,750 | SEC 申报 ↗ |
| 2025-12-09 | Rubinstein Linda M | 奖励／授予 (A) | Common Stock - Performance Stock Units | 42,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | Ozden Rabia Gurses | U (U) | Common Stock - Restricted Stock Units | 8,125 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Ozden Rabia Gurses | U (U) | Common Stock - Performance Stock Units | 85,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Ozden Rabia Gurses | 奖励／授予 (A) | Common Stock - Performance Stock Units | 85,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | Machado Patrick | U (U) | Common Stock | 8,818 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Lupher, Jr. Mark L. | U (U) | Common Stock | 13,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Fischer Laurent | U (U) | Common Stock - Restricted Stock Units | 25,000 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Fischer Laurent | U (U) | Common Stock - Performance Stock Units | 522,666 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Fischer Laurent | U (U) | Common Stock | 351,513 | USD — | USD — | SEC 申报 ↗ |
| 2025-12-09 | Fischer Laurent | 期权行权／转换 (M) | Common Stock | 150,000 | USD 4.20 | USD 630,000 | SEC 申报 ↗ |
| 2025-12-09 | Fischer Laurent | 奖励／授予 (A) | Common Stock - Performance Stock Units | 500,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | FHMLSP, L.L.C.; FHMLSP, L.P.; Frazier Life Sciences Public Fund, L.P. | U (U) | Common Stock | 4,288,949 | USD 3.56 | USD 15,268,658 | SEC 申报 ↗ |
| 2025-12-08 | Fischer Laurent | 买入 (P) | Common Stock | 117,614 | USD 4.31 | USD 506,916 | SEC 申报 ↗ |
| 2025-12-05 | Soparkar Peter | 买入 (P) | Common Stock | 50,000 | USD 4.22 | USD 211,000 | SEC 申报 ↗ |
| 2025-12-05 | Fischer Laurent | 买入 (P) | Common Stock | 11,085 | USD 4.24 | USD 47,000 | SEC 申报 ↗ |
| 2025-12-04 | Leonard Braden Michael | 卖出 (S) | Common Stock | 524,560 | USD 4.19 | USD 2,197,906 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ADVM |
| CIK | 0001501756 |
| 行业 | Healthcare |
| 细分行业 | — Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | — |
数据覆盖
| 本地 Form 4 历史 | 152 transaction lines from 2020-01-15 to 2025-12-09 45 P purchase lines · 42 S sale lines · 65 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.